Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer

Table 5 Distribution of pretreatment clinical parameters in different neoadjuvant therapy regimen groups

Variable		Capecitabine/deGramont-RT n (%) P50 (P25-P75)	mFOLFOX6 n (%) P50 (P25-P75)	mFOLFOX6-RT n (%) P50 (P25-P75)	P-value
Gender	Male	76 (66.67)	107 (66.88)	98 (77.78)	0.083
	Female	38 (33.33)	53 (33.13)	28 (22.22)
Age (yr)	≤ 60	66 (57.39)	102 (63.75)	96 (76.19)	0.007
	> 60	49 (42.61)	58 (36.25)	30 (23.81)
BMI (kg/cm2)	< 25	83 (76.85)	118 (76.62)	83 (72.17)	0.641
	≥ 25	25 (23.15)	36 (23.38)	32 (27.83)
Hemoglobin (g/L)	≤ 125	34 (34.34)	55 (39.29)	36 (36.36)	0.729
	> 125	65 (65.66)	85 (60.71)	63 (63.64)
NLR	> 3	16 (16.16)	17 (12.14)	15 (15.15)	0.646
	≤ 3	83 (83.84)	123 (87.86)	84 (84.85)
CEA (ng/mL)	> 5	56 (56.57)	79 (56.43)	56 (56.57)	1
	≤ 5	43 (43.43)	61 (43.57)	43 (43.43)
Differentiation	Moderate-poor	90 (81.08)	135 (87.1)	93 (80.17)	0.246
	Well	21 (18.92)	20 (12.9)	23 (19.83)
DTAV (cm)	< 5	61 (53.04)	62 (38.27)	58 (46.03)	0.049
	≥ 5	54 (46.96)	100 (61.73)	68 (53.97)
TL (cm)	> 3	82 (74.55)	105 (70)	91 (75.21)	0.572
	≤ 3	28 (25.45)	45 (30)	30 (24.79)
TCE	< 50%	10 (10)	22 (15.28)	12 (10.81)	0.389
	≥ 50%	90 (90)	122 (84.72)	99 (89.19)
cN	+	84 (75)	110 (73.33)	98 (79.67)	0.462
	-	28 (25)	40 (26.67)	25 (20.33)
MRF	-	85 (74.56)	119 (74.38)	88 (69.84)	0.627
	+	29 (25.44)	41 (25.63)	38 (30.16)
pCR	Non-pCR	102 (88.7)	148 (91.36)	81 (64.29)	0
	pCR	13 (11.3)	14 (8.64)	45 (35.71)
Downstaging	Bad	64 (55.65)	101 (62.35)	61 (48.41)	0.061
	Good	51 (44.35)	61 (37.65)	65 (51.59)
cT	2	9 (8.26)	10 (6.85)	2 (1.69)	0.19
	3	85 (77.98)	112 (76.71)	93 (78.81)
	4	15 (13.76)	24 (16.44)	23 (19.49)
PLT (×109/L)		230 (188.75-267.25)	236.5 (200.25-290.75)	244 (212-281)	0.168
ApoA1 (g/L)		1.31 (1.14-1.47)	1.29 (1.12-1.44)	1.28 (1.15-1.5)	0.73
ApoB (g/L)		0.97 (0.8-1.09)	0.98 (0.78-1.14)	0.98 (0.81-1.21)	0.425
The interval		54 (49-58.25)	22 (18-25.75)	52 (47-59)	0

Platelet, apolipoprotein A-1, apolipoprotein B, and the interval were calculated as metrological data, and others are counting data. pCR: Complete pathological response; NLR: Neutrophil-lymphocyte ratio; DTAV: Distance of tumor from the anal verge; TL: Tumor length; TCE: Tumor circumferential extent; NT: Neoadjuvant therapy; PLT: Platelet; ApoA1: Apolipoprotein A-1; ApoB: Apolipoprotein B; MRF: Mesorectal fascia; CEA: Carcinoembryonic antigen.